**** SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS ****
+----------------+--------------------------------------+----------+-----------+
| CAS# | Chemical Name | % | EINECS# |
|----------------|--------------------------------------|----------|-----------|
| 583-52-8 |Potassium oxalate anhydrous | - | 209-506-8 |
|----------------|--------------------------------------|----------|-----------|
| 6487-48-5 |Potassium oxalate monohydrate | > 99 | unlisted |
+----------------+--------------------------------------+----------+-----------+
Hazard Symbols: XN
Risk Phrases: 21/22
**** SECTION 3 - HAZARDS IDENTIFICATION ****
EMERGENCY OVERVIEW
Harmful in contact with skin and if swallowed.Hygroscopic.
Potential Health Effects
Eye:
May cause eye irritation. May result in corneal injury.
Skin:
Harmful if absorbed through the skin. Oxalate is an irritant and may
cause dermatitis. Skin lesions begin with epithelial cracking and the
formation of slow-healing ulcers. The fingers may appear cyanotic.
Ingestion:
Ulcerations of the mouth, vomiting of blood, and rapid appearance of
shock, convulsions, twitching, tetany, and cardiovascular collapse
may occur following ingestion of oxalic acid or its soluble salts.
Systemic effects may be due to formation of calcium oxalate which is
insoluble at physiological pH and can be deposited in the brain and
kidney tubules. Resultant hypocalcemia might disturb the function of
the heart and nerves. Mean lethal dose for oxalates in adults is
estimated at 10 - 30 grams (143 - 428 mg/kg).
Inhalation:
Inhalation of oxalic acid produces irritation of the respiratory
tract, ulceration of the mucous membranes, headaches, nervousness,
cough, vomiting, emaciation, back pain (due to kidney injury), and
weakness.
Chronic:
Inhalation of oxalic acid dust or mist over a long period of time
might result in weight loss and respiratory tract inflammation. Rats
administered oxalic acid at 2.5 and 5% in the diet for 70 days
developed depressed thyroid function and weight loss. A study of
railroad car cleaners in Norway who were heavily exposed to oxalic
acid solutions and vapors revealed a 53% prevalence of urolithiasis
(the formation of urinary stones), compared to a rate of 12% among
unexposed workers from the same company.
**** SECTION 4 - FIRST AID MEASURES ****
Eyes:
In case of contact, immediately flush eyes with plenty of water for
at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for
at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give
anything by mouth to an unconscious person.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial
respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.
Antidote:
Intravenous administration of calcium gluconate or calcium chloride
may be required if hypocalcemia or hypocalcemic tetany occur.
**** SECTION 5 - FIRE FIGHTING MEASURES ****
General Information:
As in any fire, wear a self-contained breathing apparatus in
pressure-demand, MSHA/NIOSH (approved or equivalent), and full
protective gear. During a fire, irritating and highly toxic gases
may be generated by thermal decomposition or combustion. Use water
spray to keep fire-exposed containers cool.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.
**** SECTION 6 - ACCIDENTAL RELEASE MEASURES ****
General Information: Use proper personal protective equipment as indicated
in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal
container. Clean up spills immediately, observing precautions in the
Protective Equipment section. Avoid generating dusty conditions.
Flush spill area with water. Provide ventilation.
**** SECTION 7 - HANDLING and STORAGE ****
Handling:
Wash thoroughly after handling. Remove contaminated clothing and
wash before reuse. Minimize dust generation and accumulation. Do not
get in eyes, on skin, or on clothing. Keep container tightly closed.
Do not ingest or inhale. Discard contaminated shoes. Use only with
adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry,
well-ventilated area away from incompatible substances. Store
protected from moisture. Oxalates slowly corrode steel.
**** SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION ****
Engineering Controls:
Facilities storing or utilizing this material should be equipped
with an eyewash facility and a safety shower. Use adequate
ventilation to keep airborne concentrations low.
Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical
safety goggles as described by OSHA's eye and face
protection regulations in 29 CFR 1910.133 or European
Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin
exposure.
Clothing:
Wear appropriate protective clothing to prevent skin
exposure.
Respirators:
A respiratory protection program that meets OSHA's 29
CFR ??1910.134 and ANSI Z88.2 requirements or European
Standard EN 149 must be followed whenever workplace
conditions warrant a respirator's use.
**** SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES ****
Physical State: Crystals
Appearance: white
Odor: odorless
pH: neutral in solution
Vapor Pressure: Negligible.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 356 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: 364 G/L IN WATER (20C)
Specific Gravity/Density: 2.13
Molecular Formula: C2O4K2.H2O
Molecular Weight: 184.24
**** SECTION 10 - STABILITY AND REACTIVITY ****
Chemical Stability:
Stable.
Conditions to Avoid:
Dust generation, moisture, excess heat, Oxalates slowly corrode
steel..
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon
dioxide, formic acid, dipotassium oxide.
Hazardous Polymerization: Will not occur.
**** SECTION 11 - TOXICOLOGICAL INFORMATION ****
RTECS#:
CAS# 583-52-8: RO2885000
CAS# 6487-48-5 unlisted.
LD50/LC50:
Not available.
Not available.
Carcinogenicity:
Potassium oxalate anhydrous -
Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
Potassium oxalate monohydrate -
Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
See actual entry in RTECS for complete information.
**** SECTION 12 - ECOLOGICAL INFORMATION ****
**** SECTION 13 - DISPOSAL CONSIDERATIONS ****
Dispose of in a manner consistent with federal, state, and local regulations.
**** SECTION 14 - TRANSPORT INFORMATION ****
IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Dangerous Goods Code: 6.1(25C)
UN Number: 2811
**** SECTION 15 - REGULATORY INFORMATION ****
European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 21/22 Harmful in contact with skin and if
swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 583-52-8: No information available.
CAS# 6487-48-5: 1
United Kingdom Occupational Exposure Limits
Canada
CAS# 583-52-8 is listed on Canada's DSL List.
CAS# 583-52-8 is not listed on Canada's Ingredient Disclosure List.
CAS# 6487-48-5 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
US FEDERAL
TSCA
CAS# 583-52-8 is listed on the TSCA inventory.
CAS# 6487-48-5 is not listed on the TSCA inventory.
It is for research and development use only.
**** SECTION 16 - ADDITIONAL INFORMATION ****
MSDS Creation Date: 10/12/1998 Revision #3 Date: 5/24/2001
The information above is believed to be accurate and represents the best
information currently available to us. However, we make no warranty of
merchantability or any other warranty, express or implied, with respect to
such information, and we assume no liability resulting from its use. Users
should make their own investigations to determine the suitability of the
information for their particular purposes. In no way shall the company be
liable for any claims, losses, or damages of any third party or for lost
profits or any special, indirect, incidental, consequential or exemplary
damages, howsoever arising, even if the company has been advised of
the possibility of such damages.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
|
|
|
| ALL MSDS PAGES IN THIS GROUP
| | NAME | CAS |
|
Allyldimethylchlorosilane, 97%
| 4028-23-3 |
|
Isopropylmethyldichlorosilane, 97%
| 18236-89-0 |
|
Potassium dichromate, 99.5%
| 7778-50-9 |
|
Allyl ether, 99%
| 557-40-4 |
|
N-Decanoic Anhydride, 98%
| 2082-76-0 |
|
2,2-Dimethyl-1,3-Dioxolane, 99%
| 2916-31-6 |
|
Methylene Blue (Pract), 75% (Titr.)
| 61-73-4 |
|
Diethyl 3,3-Dimethylcyclopent-1-Enylphosphonate, 98%
| 0-01-1 |
|
Ammonium molybdate tetrahydrate, certified ACS, crystalline
| 12027-67-7 |
|
Tris(6,6,7,7,8,8,8-Heptafluoro-2,2-
| 18323-96-1 |
|
(3,3-Dimethylcyclopent-1-enylmethyl)trimethylsilane, 97%
| 0-01-1 |
|
2,4-Dimethoxy-1-Nitrobenzene, 98%
| 4920-84-7 |
|
2-Methylpropyl 3,5-Diamino-4-Chlorobenzoate
| 32961-44-7 |
|
Phthalic Acid Monopotassium Salt, 99+% (Titr.)
| 877-24-7 |
|
Ammonium nitrate
| 6484-52-2 |
|
Diethyl 3,3-Dimethylcyclohex-1-Enylphosphonate, 98%
| 109467-69-8 |
|
4-Amino-N,N-Diethyl-m-Toluidine Hydrochloride, 98%
| 148-71-0 |
|
(3,3-Dimethylcyclohex-1-enylmethyl)trimethylsilane, 98%
| 0-01-1 |
|
2-Phenylmercaptomethylbenzoic Acid, 98%
| 1699-03-2 |
|
Rhein, Tech. 90%
| 478-43-3 |
|
Potassium hydroxide, pellets, p.a.
| 1310-58-3 |
|
Salicylideneaniline, 98%
| 779-84-0 |
|
2,6-Diaminopurine
| 1904-98-9 |
|
N-Alpha-Carbobenzyloxy-L-Arginine, 98%
| 1234-35-1 |
|
Methylphenylvinylsilane
| 17878-39-6 |
|
Potassium Iodate, P.A.
| 7758-05-6 |
|
Potassium Metabisulfite
| 16731-55-8 |
|
Potassium Nitrite, Reagent ACS (Crystals), 96+% (Titr.)
| 7758-09-0 |
|
Dimethylmethoxy-n-octylsilane
| 93804-29-6 |
|
Potassium oxalate monohydrate, reagent ACS
| 583-52-8 |
|
Dodecamethylpentasiloxane, 97%
| 141-63-9 |
|
Potassium periodate (meta), 99+% (titr.)
| 7790-21-8 |
|
(4-Nitrophenyl)Octyl Ether, 99%
| 49562-76-7 |
|
1-Methoxy-1-methylamino-2-nitroethylene, 98%
| 110763-36-5 |
|
3-Hydroxy-1,2,3-Benzotriazin-4(3H)-One, 98%
| 28230-32-2 |
|
Strontium peroxide, 90-95%
| 1314-18-7 |
|
1,1,3,3,5,5-Hexamethyltrisiloxane, 97%
| 1189-93-1 |
|
Phosphorus pentachloride
| 10026-13-8 |
|
Potassium Permanganate, P.A.
| 7722-64-7 |
|
Astaxanthin
| 471-53-4 |
|
Thapsigargin
| 67526-95-8 |
|
Wortmannin
| 19545-26-7 |
|
AMT.hydrochloride
| 1121-91-1 |
|
Potassium Persulfate, Reagent ACS (Crystals), 99+% (Titr.)
| 7727-21-1 |
|
3-Bromo-7-nitroindazole
| 74209-34-0 |
|
Potassium phosphate tribasic monohydrate
| 7778-53-2 |
|
Methyl 4-aminobenzoate, 98%
| 619-45-4 |
|
Carboxy-PTIO
| 148819-94-7 |
|
1,4-Dibromobutane, 97%
| 110-52-1 |
|
tert-Butylhydroquinone, 97%
| 1948-33-0 |
|
|